Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 140 of 6351
-
Gene therapy could end frequent eye injections for wet AMD
Disease control OngoingABBV-RGX-314 (also known as RGX-314) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD or nAMD). Wet AMD is characterized by loss of vision due to new, leaky blood vessel formation in the retina. W…
Phase 2/3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Can a Two-Drug combo tame Hard-to-Treat pancreatic cancer?
Disease control CompletedThis phase II trial studies how well niraparib and dostarlimab work in treating patients with germline or somatic BRCA1/2 and PALB2 mutated pancreatic cancer that has spread to other places in the body (metastatic). Niraparib may stop the growth of tumor cells by blocking some of…
Phase 2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can a new drug target Hard-to-Treat kidney and ovarian cancers?
Disease control OngoingThis clinical trial will evaluate raludotatug deruxtecan (R-DXd; DS-6000a) in participants with advanced renal cell carcinoma (RCC) and ovarian cancer (OVC). The main goals of this study will be to investigate the recommended dose of R-DXd that can be given safely to participants…
Phase 1 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Alpha radiation seeds target tumors from the inside
Disease control Recruiting nowA unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for superficial cutaneous, mucosal or soft tissue neoplasia
Sponsor: Alpha Tau Medical LTD. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug cocktail shows promise for Hard-to-Treat colorectal cancer
Disease control OngoingThe purpose of this study is to evaluate two study medicines (encorafenib plus cetuximab) taken alone or together with standard chemotherapy for the potential treatment of colorectal cancer that: * has spread to other parts of the body (metastatic); * has a certain type of abnor…
Phase 3 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Double immunotherapy attack shows promise in tough lung cancer
Disease control OngoingThe purpose of this multicenter study in China is to evaluate the safety and efficacy of tiragolumab plus atezolizumab and carboplatin and etoposide (CE) compared with placebo plus atezolizumab and CE in participants with untreated extensive-stage small cell lung cancer.
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New drug combo before surgery shows promise for lung cancer patients
Disease control OngoingThis is a Phase III, randomised, controlled, 3-arm, multi-centre study of neoadjuvant osimertinib as monotherapy or in combination with chemotherapy, versus SoC chemotherapy alone, for the treatment of patients with resectable EGFRm Non-Small Cell Lung Cancer
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 10, 2026 03:00 UTC
-
Triple-drug inhaler aims to tame severe asthma in teens and adults
Disease control CompletedThis is a variable length study to evaluate the efficacy and safety of budesonide/glycopyrronium/formoterol inhaler in adults and adolescents with severe asthma inadequately controlled with standard of care
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New gel could slash infection risk after abdominal surgery
Prevention CompletedPhase III, Prospective, Multinational, Multicenter, Randomized, Controlled, Two-arm, Double Blind Study to Assess Efficacy and Safety of D-PLEX Administered Concomitantly with the Standard of Care (SoC), Compared to a SoC Treated Control Arm, in Prevention of Post Abdominal Surge…
Phase 3 • Sponsor: PolyPid Ltd. • Aim: Prevention
Last updated Jul 15, 2026 00:00 UTC
-
Moderna vaccine shows promise for teens in large trial
Vaccine CompletedThe mRNA-1273 vaccine is being developed to prevent COVID-19, the disease resulting from Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) infection. The study is designed to primarily evaluate the safety, reactogenicity, and effectiveness of mRNA-1273 vaccine administer…
Phase 2/3 • Sponsor: ModernaTX, Inc. • Aim: Vaccine
Last updated Jun 26, 2026 17:09 UTC
-
Weekly injection helps shed pounds in major weight loss trial
Disease control CompletedThis study will look at the change in body weight from the start to the end of the study. The purpose of the study is to compare the effect on body weight in people taking semaglutide (a new medicine) and people taking "dummy" medicine. In addition to taking the medicine particip…
Phase 3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Electric field therapy plus standard treatment shows promise for deadly brain cancer
Disease control CompletedTo test the effectiveness and safety of Optune® given concomitantly with radiation therapy (RT) and temozolomide (TMZ) in newly diagnosed GBM patients, compared to radiation therapy and temozolomide alone. In both arms, Optune® and maintenance temozolomide are continued following…
Sponsor: NovoCure Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Lung cancer hope: drug combo aims to boost survival in Early-Stage disease
Disease control OngoingResearchers are looking for new ways to treat Limited-Stage Small Cell Lung Cancer (LS-SCLC), a type of lung cancer that has not spread from the lung to other parts of the body. The purpose of this study is to learn if pembrolizumab and olaparib, when given with chemotherapy and …
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Bladder cancer patients may skip surgery with new drug combo
Disease control OngoingThe purpose of study is to compare bladder intact-event free survival (BI-EFS) in participants receiving TAR-200 in combination with intravenous (IV) cetrelimab versus concurrent chemoradiotherapy.
Phase 3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New drug may offer better protection against breast cancer return
Disease control OngoingPatients with HER2-positive primary breast cancer (BC) who do not achieve complete response after appropriate neoadjuvant therapy are at higher risk of disease recurrence. More effective treatment options are needed for this patient population. This study will examine the efficac…
Phase 3 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Gene therapy offers hope for rare blindness
Disease control CompletedA clinical trial of AAV5-RPGR vector for participants with X-linked retinitis pigmentosa (XLRP)
Phase 3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Gene therapy shows promise for rare blindness disease
Disease control OngoingA clinical trial of AAV5-hRKp.RPGR vector for participants with X-linked retinitis pigmentosa (XLRP)
Phase 3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Immune cell therapy shows promise for aggressive blood cancer
Disease control Recruiting nowA Study of CD19 CAR-T Therapy for Patients With Newly Diagnosed High-risk Large B-cell Lymphoma
Phase 2 • Sponsor: Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New hope for hard-to-treat lung cancer: targeted drug plus immunotherapy tested
Disease control Recruiting nowThe Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS and who are candidates for first-line treatment. The Phase 3 port…
Phase 2/3 • Sponsor: Mirati Therapeutics Inc. • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Four-Drug cocktail aims to shrink pancreatic tumors before surgery
Disease control CompletedTo evaluate the normalization rate of CA 19-9 of individuals with non-metastatic pancreas cancer following up to 6 months of neoadjuvant chemotherapy.
Phase 2 • Sponsor: HonorHealth Research Institute • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC